[HTML][HTML] A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
Most neutralizing anti-SARS-CoV-2 monoclonal antibodies (mAbs) target the receptor
binding domain (RBD) of the spike (S) protein. Here, we characterize a panel of mAbs …
binding domain (RBD) of the spike (S) protein. Here, we characterize a panel of mAbs …
[HTML][HTML] Impact of the B. 1.1. 7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
C Graham, J Seow, I Huettner, H Khan, N Kouphou… - bioRxiv, 2021 - ncbi.nlm.nih.gov
The interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the ACE2
receptor on host cells is essential for viral entry. RBD is the dominant target for neutralizing …
receptor on host cells is essential for viral entry. RBD is the dominant target for neutralizing …
[HTML][HTML] Construction of a large size human immunoglobulin heavy chain variable (VH) domain library, isolation and characterization of novel human antibody VH …
Phage display is a well-established technology for in vitro selection of monoclonal
antibodies (mAb), and more than 12 antibodies isolated from phage displayed libraries of …
antibodies (mAb), and more than 12 antibodies isolated from phage displayed libraries of …
[HTML][HTML] Discovery of antivirals using phage display
The latest coronavirus disease outbreak, COVID-19, has brought attention to viral infections
which have posed serious health threats to humankind throughout history. The rapid global …
which have posed serious health threats to humankind throughout history. The rapid global …
[HTML][HTML] In vivo electroporation of plasmid DNA: a promising strategy for rapid, inexpensive, and flexible delivery of anti-viral monoclonal antibodies
S Pagant, RA Liberatore - Pharmaceutics, 2021 - mdpi.com
Since the first approval of monoclonal antibodies by the United States Food and Drug
Administration (FDA) in 1986, therapeutic antibodies have become one of the predominant …
Administration (FDA) in 1986, therapeutic antibodies have become one of the predominant …
Animal models for studying coronavirus infections and developing antiviral agents and vaccines
In addition to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East
respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 has become the third deadly …
respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 has become the third deadly …
[HTML][HTML] Antibody protection from SARS-CoV-2 respiratory tract exposure and infection
The COVID-19 pandemic has underscored the need to understand the dynamics of SARS-
CoV-2 respiratory infection and protection provided by the immune response. SARS-CoV-2 …
CoV-2 respiratory infection and protection provided by the immune response. SARS-CoV-2 …
[HTML][HTML] Slaying SARS-CoV-2 one (single-domain) antibody at a time
Camelid-derived and synthetic single-domain antibodies (sdAbs) are emerging as potent
weapons against the novel coronavirus, SARS-CoV-2. sdAbs are small, compact …
weapons against the novel coronavirus, SARS-CoV-2. sdAbs are small, compact …
[HTML][HTML] GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
G Pascual-Pasto, B McIntyre, R Shraim… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background Antibody–drug conjugates (ADCs) that deliver cytotoxic drugs to tumor cells
have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic …
have emerged as an effective and safe anticancer therapy. ADCs may induce immunogenic …
[HTML][HTML] Point mutations in SARS-CoV-2 variants induce long-range dynamical perturbations in neutralizing antibodies
D Ray, RN Quijano, I Andricioaei - Chemical science, 2022 - pubs.rsc.org
Monoclonal antibodies are emerging as a viable treatment for the coronavirus disease 19
(COVID-19). However, newly evolved variants of the severe acute respiratory syndrome …
(COVID-19). However, newly evolved variants of the severe acute respiratory syndrome …